CJC-1295
CJC-1295 is a GHRH analog. Two different forms exist. Only Phase 1 human data support it.
Checked by the PU Research editorial team — evidence-graded against primary sources. Last check: 23 July 2026. Sources: 3. Who checks this
Sport prohibition notice. WADA prohibits GHRH analogs and growth hormone secretagogues under section S2.2.4. Seven of the eight compounds in this category fall under that section. IGF-1 LR3 falls under S2, and its insulin cross-activity also relates to S4. Check the live WADA list before any decision that involves competition.
01Identity & Classification
CJC-1295 is a GHRH analog. Two pharmacologically different forms carry this name.
- CJC-1295 with DAC. DAC means Drug Affinity Complex. This form binds albumin.
- CJC-1295 without DAC. This form is also called modified GRF 1-29.
The two forms behave differently. Read the name on any source before you read its claim.
02Mechanism: How It Works
CJC-1295 binds the GHRH receptor on the pituitary gland.
The DAC form binds serum albumin through a covalent bond. That bond extends the half-life from minutes to days. It holds growth hormone and IGF-1 at a raised level.
03Research Findings
Evidence tier: clinical, Phase 1 pharmacokinetics.
Teichman et al. (2006) recorded a sustained increase in growth hormone and IGF-1 after one injection.
Evidence limit. No large outcome trial exists. No published trial measures body composition or recovery.
04Reported Dosing & Delivery
No clinical dosing source exists for a body-composition use. Non-clinical community protocols exist for the DAC form. No clinical evidence supports them, and this site does not publish them.
Not approved for human use.
05Pharmacokinetics & Timing
- DAC form: half-life about 6 to 8 days.
- No-DAC form: half-life about 30 minutes, with a more pulsatile release.
06Interactions & Combinations
Community protocols combine CJC-1295 with Ipamorelin. That combination is anecdotal. No published human randomized controlled trial tests it.
The keyword data show high public interest in this pair. The evidence base does not match that interest.
Compare with Sermorelin.
07Safety & Contraindications
Human safety data are limited. Injection site reactions occurred.
08Monitoring & Biomarkers
- IGF-1.
- Glucose.
09Regulatory Status
No regulator approves CJC-1295. In April 2026 the FDA removed it from 503A Category 2 after the nomination was withdrawn. A pharmacy cannot compound it.
WADA prohibits it under S2.2.4. See the WADA prohibited list status.
10Works Cited
- 01Teichman SL, et al. Journal of Clinical Endocrinology & Metabolism, 2006. View source →
- 02Ionescu M, Frohman LA. Journal of Clinical Endocrinology & Metabolism, 2006. View source →
- 03WADA 2025 Prohibited List, section S2.2.4. View source →
More in Growth Hormone Axis
Open the Growth Hormone category →Tesamorelin
Tesamorelin is a growth hormone-releasing factor analog. The FDA approves it for one indication only.
Sermorelin
Sermorelin is a GHRH 1-29 analog. It held FDA approval as a diagnostic agent until 2008.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue. Human pharmacokinetic data exist. No outcome trial exists.
Research use only. This is not medical advice.
PeptideUnlock gives education. Nothing here diagnoses a condition. Nothing here recommends a compound or a dose.
Most peptides on this site have no approval for human use in any country. Some carry documented harms. Several are prohibited in sport.
Regulatory status changes by country and by month. Check the current rule where you live. Speak to a licensed clinician before any health decision.